Pathological characteristics and features of male breast cancer, BRCA- and non-BRCA-related, and of other cancers associated with BRCA1/2 mutations seen in males
Please Note: All papers in this LitList are included in "Pathology / Tissue/Cellular Phenotype ~ Phenotype / Expression / Risk Spectrum of HBOC" as well.
List was last updated on
.-
- Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.
- Chatterji S, Krzoska E, Thoroughgood CW, Saganty J, Liu P, Elsberger B, Abu-Eid R, Speirs V.
- Lancet Oncol. 2023 Feb;24(2):e74-e85. doi: 10.1016/S1470-2045(22)00633-7.
- PMID: 36725152
- PubMed abstract
- Source abstract
•• Podcast:
In conversation with... Valerie Speirs.
-
- Histopathological results of radical prostatectomy specimen of men younger than 50 years of age at the time of surgery: possible implications for prostate cancer screening programs?
- Mehring G, Tilki D, Heinzer H, Steuber T, Pose RM, Thederan I, Budäus L, Salomon G, Haese A, Michl U, Maurer T, Huland H, Graefen M, Isbarn H.
- World J Urol. 2023 Jan 19. doi: 10.1007/s00345-023-04287-1. Epub ahead of print.
- PMID: 36656332
- PubMed abstract
-
- CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
- Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L.
- Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y.
- PMID: 36650183
- PubMed abstract
-
- Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
- Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R, Saya H.
- Cancer Med. 2023 Jan 16. doi: 10.1002/cam4.5617. Epub ahead of print.
- PMID: 36645189
- PubMed abstract
- Source abstract
-
- Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology.
- Valentini V, Silvestri V, Bucalo A, Conti G, Karimi M, Di Francesco L, Pomati G, Mezi S, Cerbelli B, Pignataro MG, Nicolussi A, Coppa A, D'Amati G, Giannini G, Ottini L.
- Front Oncol. 2022 Dec 12;12:1092201. doi: 10.3389/fonc.2022.1092201.
-
- Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.
- Shimomura A, Yoshida M, Kubo T, Yamashita S, Noguchi E, Nagayama A, Hanamura T, Okazaki M, Mukohara T, Tsuruga A, Tanaka K, Kawamura Y, Higuchi T, Takahashi Y, Kurozumi S, Hayashida T, Ichikawa H, Ushijima T, Suto A.
- Breast Cancer Res Treat. 2022 Dec 9. doi: 10.1007/s10549-022-06822-x. Epub ahead of print.
- PMID: 36494460
- PubMed abstract
-
- Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.
- Poon DM, Azad A, Castro E, Kanesvaran R, Sartor O.
- Front Oncol. 2022 Nov 21;12:1101678. doi: 10.3389/fonc.2022.1101678.
- Commentary
- Free Full Text
•• Original research:
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA.
- PMID: 36185208
- PubMed abstract
- Free Full Text
•• Original research:
Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
- PMID: 35924163
- PubMed abstract
- Free Full Text
-
- Precision Medicine Provides Continued Benefit in mCRPC.
- George DJ, Scott R.
- OncLive. 2022 Nov 21.
- Review
- Free Full Text
-
- Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.
- Han H, Park CK, Cho NH, Lee J, Jang WS, Ham WS, Choi YD, Cho KS.
- Int J Mol Sci. 2022 Nov 3;23(21):13426. doi: 10.3390/ijms232113426.
-
- Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients.
- Dogan I, Aydin E, Yazici H, Saip P.
- Eur J Breast Health. 2022 Oct 1;18(4):323-328. doi: 10.4274/ejbh.galenos.2022.2022-5-2.
- PMID: 36248747
- PubMed abstract
-
- B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
- Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, Fenor de la Maza MD, Rescigno P, Westaby D, Chandran K, Riisnaes R, Ferreira A, Miranda S, Calì B, Alimonti A, Bressan S, Nguyen AHT, Shen MM, Hawley JE, Obradovic A, Drake CG, Bertan C, Baker C, Tunariu N, Yuan W, de Bono JS.
- Eur Urol. 2022 Sep 13:S0302-2838(22)02633-1. doi: 10.1016/j.eururo.2022.09.004. Epub ahead of print.
- PMID: 36114082
- PubMed abstract
-
- What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
- Petrylak DP, Watkins SP, Loehr A.
- Front Oncol. 2022 Aug 1;12:951348. doi: 10.3389/fonc.2022.951348.
- PMID: 35978838
- PubMed abstract
- Case report
- Free PMC article
- Free Full Text
-
- Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients.
- Kanski A.
- Precision Oncology News. Biomarkers. BRCA. 2022 Jul 13.
Original research:
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
- PMID: 35772050
- PubMed abstract
- Free Full Text
-
- Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
- Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J.
- JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195.
- PMID: 35820087
- PubMed abstract
- Source abstract
-
- A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
- Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M.
- BMC Med Genomics. 2022 Jun 20;15(1):138. doi: 10.1186/s12920-022-01286-w.
- PMID: 35725469
- PubMed abstract
- Case report
- Free Full Text
-
- The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer.
- Kensler KH, Baichoo S, Pathania S, Rebbeck TR.
- NPJ Precis Oncol. 2022 Jun 17;6(1):39. doi: 10.1038/s41698-022-00284-6.
- PMID: 35715489
- PubMed abstract
-
- Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
- Dehdashti F, Reimers MA, Shoghi KI, Chen DL, Luo J, Rogers B, Pachynski RK, Sreekumar S, Weimholt C, Zhou D.
- Mol Imaging Biol. 2022 Jun 14. doi: 10.1007/s11307-022-01746-w. Epub ahead of print.
- PMID: 35701722
- PubMed abstract
-
- Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study.
- Colosini A, Bernardi S, Foroni C, Pasinetti N, Guerini AE, Russo D, Bresciani R, Tomasi C, Magrini SM, Bardoscia L, Triggiani L.
- Biomedicines. 2022 Jun 4;10(6):1321. doi: 10.3390/biomedicines10061321.
- PMID: 35740343
- PubMed abstract
- Source abstract
-
- PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
- Sokol ES, Jin DX, Fine A, Trabucco SE, Maund S, Frampton G, Molinero L, Antonarakis ES.
- JCO Precis Oncol. 2022 Jun;6:e2100531. doi: 10.1200/PO.21.00531.
- PMID: 35772050
- PubMed abstract
- Source abstract
Research news: Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients. (Precision Oncology News)
-
- Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.
- Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M; PEACE Consortium, Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW, Beltran H, Attard G, Demichelis F.
- NAR Cancer. 2022 May 27;4(2):zcac016. doi: 10.1093/narcan/zcac016.
- PMID: 35664542
- PubMed abstract
-
- Alterations in homologous recombination repair genes in prostate cancer brain metastases.
- Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins SA, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch H, Thalmann G, Ng CKY, Gillessen S, Piscuoglio S, Rubin MA.
- Nat Commun. 2022 May 3;13(1):2400. doi: 10.1038/s41467-022-30003-5.
- PMID: 35504881
- PubMed abstract
-
- Male Breast Cancer: From Molecular Genetics to Clinical Management.
- Pensabene M, Von Arx C, De Laurentiis M.
- Cancers (Basel). 2022 Apr 15;14(8):2006. doi: 10.3390/cancers14082006.
- PMID: 35454911
- PubMed abstract
- Source abstract
- Review
- Free PMC article
- Free Full Text
-
- Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study.
- Macrini S, Francesconi S, Caprera C, Lancia D, Corsi M, Gunnellini M, Rocchi A, Pireddu A, Marziani F, Mosillo C, Calandrella ML, Caserta C, Giannarelli D, Guida A, Ascani S, Bracarda S.
- Cancers (Basel). 2022 Mar 17;14(6):1542. doi: 10.3390/cancers14061542.
- PMID: 35326693
- PubMed abstract
- Source abstract
-
- DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
- Zhu S, Zhang Z, Zhang H, Liu Z, Liu M, Liu Q, Zang L, Wang L, Ji J, Wu B, Sun L, Zhang Z, Cao H, Wang Y, Wang H, Shang Z, Niu Y.
- Prostate. 2022 Mar;82(4):464-474. doi: 10.1002/pros.24292. Epub 2022 Jan 17.
- PMID: 35037281
- PubMed abstract
- Source abstract
-
- RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
- Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, Wang Z, Azuma H, Szallasi Z, Mouw KW, Zou L, Kibel AS, Jia L.
- Sci Adv. 2022 Feb 18;8(7):eabl9794. doi: 10.1126/sciadv.abl9794. Epub 2022 Feb 18.
- PMID: 35179959
- PubMed abstract
- Source abstract
-
- Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients.
- Chen W, Xia W, Xue S, Huang H, Lin Q, Liu Y, Liu T, Zhang Y, Zhang P, Wang J, Yang Y, Dong B, Yu Z.
- Front Oncol. 2022 Feb 17;12:746102. doi: 10.3389/fonc.2022.746102.
- PMID: 35251954
- PubMed abstract
-
- What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.
- Palicelli A, Croci S, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Zanelli M, Chaux A, Cañete-Portillo S, Bonasoni MP, Ascani S, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Gandhi J, Nicoli D, Farnetti E, Piana S, Tafuni A, Bonacini M.
- Biomedicines. 2022 Jan 22;10(2):236. doi: 10.3390/biomedicines10020236.
- PMID: 35203446
- PubMed abstract
- Source abstract
- Review
- Free PMC article
- Free Full Text
-
- Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors.
- Stopsack KH, Nandakumar S, Arora K, Nguyen B, Vasselman SE, Nweji B, McBride SM, Morris MJ, Rathkopf DE, Slovin SF, Danila DC, Autio KA, Scher HI, Mucci LA, Solit DB, Gönen M, Chen Y, Berger MF, Schultz N, Abida W, Kantoff PW.
- Clin Cancer Res. 2022 Jan 15;28(2):318-326. doi: 10.1158/1078-0432.CCR-21-2577. Epub 2021 Oct 19.
- PMID: 34667026
- PubMed abstract
- Source abstract
-
- Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report.
- Zhuang J, Zhang S, Qiu X, Fu Y, Ai S, Zhao T, Yang Y, Guo H.
- Front Oncol. 2022 Jan 5;11:777318. doi: 10.3389/fonc.2021.777318.
- PMID: 35070981
- PubMed abstract
- Case report
- Free PMC article
- Free Full Text
-
- Invasive Breast Carcinoma: Rare Clinical Presentation in a Male Patient.
- Hanna M, Solly M.
- Cureus. 2021 Dec 20;13(12):e20547. doi: 10.7759/cureus.20547.
- PMID: 35103127
- PubMed abstract
- Case report
- Free PMC article
- Free Full Text
-
- Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
- De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS.
- JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789.
- PMID: 34877933
- PubMed abstract
-
- Prognostic difficulties of men with breast cancer.
- Fentiman IS.
- Breast J. 2021 Dec;27(12):877-882. doi: 10.1111/tbj.14297. Epub 2021 Oct 15.
- PMID: 34652050
- PubMed abstract
- Source abstract
-
- Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
- Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K.
- Eur J Cancer. 2021 Dec;159:87-97. doi: 10.1016/j.ejca.2021.09.029. Epub 2021 Nov 2.
- PMID: 34742160
- PubMed abstract
- Source abstract
-
- Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
- Lieb V, Abdulrahman A, Weigelt K, Hauch S, Gombert M, Guzman J, Bellut L, Goebell PJ, Stöhr R, Hartmann A, Wullich B, Taubert H, Wach S.
- Cells. 2021 Nov 18;10(11):3223. doi: 10.3390/cells10113223.
- PMID: 34831445
- PubMed abstract
- Source abstract
-
- Genomic Features of Radiation-Associated Muscle-Invasive Bladder Cancer.
- Muralidhar V, Carvalho F, Preston M, Curran C, Freeman D, Sonpavde G, Kibel A, Van Allen EM, Mossanen M, Mouw KW.
- Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S13-S14. doi: 10.1016/j.ijrobp.2021.07.062.
- PMID: 34700458
- PubMed abstract
- Conference abstract
- Free Full Text
-
- Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
- Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS.
- Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27.
- PMID: 34045297
- PubMed abstract
-
- Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.
- McFarland TR, Tandar CE, Agarwal N, Swami U.
- Cancer Treat Res Commun. 2021;29:100480. doi: 10.1016/j.ctarc.2021.100480. Epub 2021 Oct 20.
- PMID: 34700141
- PubMed abstract
- Case report
- Free Full Text
-
- First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.
- Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M.
- IJU Case Rep. 2021 Oct 20;5(1):41-44. doi: 10.1002/iju5.12383.
- PMID: 35005470
- PubMed abstract
- Source abstract
-
- [The Clinical Utility of Liquid Biopsies as Biomarkers in Metastatic Prostate Cancer].
- Sumiyoshi T, Akamatsu S.
- Gan To Kagaku Ryoho. 2021 Oct;48(10):1203-1208. Japanese.
- PMID: 34657048
- PubMed abstract
- Source abstract
-
- Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.
- Wattenberg MM, Reiss KA.
- Cancers (Basel). 2021 Sep 21;13(18):4716. doi: 10.3390/cancers13184716.
- PMID: 34572943
- PubMed abstract
- Source abstract
- Review
- Free PMC article
- Free Full Text
-
- Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
- Kaur HB, Vidotto T, Mendes AA, Salles DC, Isaacs WB, Antonarakis ES, Lotan TL.
- Cancer Immunol Immunother. 2021 Sep 17. doi: 10.1007/s00262-021-03050-y. Epub ahead of print.
- PMID: 34533610
- PubMed abstract
- Source abstract
-
- Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.
- Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S.
- Clin Cancer Res. 2021 Sep 15:clincanres.2328.2021. doi: 10.1158/1078-0432.CCR-21-2328. Epub ahead of print.
- PMID: 34526361
- PubMed abstract
- Source abstract
-
- A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk.
- Liu D, Zhu J, Zhou D, Nikas EG, Mitanis NT, Sun Y, Wu C, Mancuso N, Cox NJ, Wang L, Freedland SJ, Haiman CA, Gamazon ER, Nikas JB, Wu L.
- Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33808. Epub ahead of print.
- PMID: 34520569
- PubMed abstract
- Source abstract
-
- Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
- Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S.
- Int J Mol Sci. 2021 Sep 10;22(18):9783. doi: 10.3390/ijms22189783.
- PMID: 34575947
- PubMed abstract
- Source abstract
- Review
- Free PMC article
- Free Full Text
-
- Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium.
- Iacovelli R, Astore S, Ciccarese C, Cannella MA, Bove P, Iacovelli V, Tortora G.
- Expert Rev Anticancer Ther. 2021 Sep 9:1-4. doi: 10.1080/14737140.2021.1976148. Epub ahead of print.
- PMID: 34493147
- PubMed abstract
- Source abstract
-
- Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance.
- Zelli V, Silvestri V, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, Coppa A, Giannini G, Cortesi L, Calistri D, Tibiletti MG, Fox SB, Fab K, Palli D, Ottini L.
- Cancers (Basel). 2021 Sep 8;13(18):4515. doi: 10.3390/cancers13184515.
- PMID: 34572741
- PubMed abstract
- Source abstract
-
- Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
- Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B.
- JAMA Oncol. 2021 Jun 4 [2021 Sept];7(9):1–5 [1378-1382]. doi: 10.1001/jamaoncol.2021.2350. Epub ahead of print.
- PMID: 34086042
- PubMed abstract
-
- Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.
- Hesterberg AB, Gordetsky JB, Hurley PJ.
- Urology. 2021 Sep;155:47-54. doi: 10.1016/j.urology.2021.05.028. Epub 2021 May 28.
- PMID: 34058243
- PubMed abstract
- Source abstract
-
- Male breast cancer: an update.
- Fox S, Speirs V, Shaaban AM.
- Virchows Arch. 2021 Aug 30. doi: 10.1007/s00428-021-03190-7. Epub ahead of print.
- PMID: 34458944
- PubMed abstract
- Source abstract
-
- Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
- Boilève A, Lavaud P, Caron O.
- Eur Urol Oncol. 2021 Aug;4(4):674-675. doi: 10.1016/j.euo.2021.06.004. Epub 2021 Jun 19.
- PMID: 34154978
- PubMed abstract
- Source abstract
Review:
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
- PMID: 33390340
- PubMed abstract
- Free Full Text
-
- Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
- Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.
- JCO Precis Oncol. 2021 Jul 22;5:PO.21.00070. doi: 10.1200/PO.21.00070.
- PMID: 34778690
- PubMed abstract
- Source abstract
-
- Circulating tumor DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
- Zhao J, Sun G, Zhu S, Dai J, Chen J, Zhang M, Ni Y, Zhang H, Shen P, Zhao X, Zhang B, Pan X, Nie L, Yin X, Liang J, Zhang X, Wang Z, Zhu X, Liao B, Liu Z, Armstrong CM, Gao AC, Huang H, Chen N, Zeng H.
- BJU Int. 2021 Jun 29. doi: 10.1111/bju.15530. Epub ahead of print.
- PMID: 34185954
- PubMed abstract
- Source abstract
-
- A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
- Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ.
- Clin Cancer Res. 2021 Jun 24:clincanres.0121.2021. doi: 10.1158/1078-0432.CCR-21-0121. Epub ahead of print.
- PMID: 34168052
- PubMed abstract
- Source abstract
-
- Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
- Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, T'Kint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ.
- Prostate Cancer Prostatic Dis. 2021 Jun 9. doi: 10.1038/s41391-021-00397-2. Epub ahead of print.
- PMID: 34108647
- PubMed abstract
- Source abstract
-
- Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
- Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Macé S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS.
- Eur Urol. 2021 Jun 5:S0302-2838(21)01799-1. doi: 10.1016/j.eururo.2021.05.030. Epub ahead of print.
- PMID: 34103179
- PubMed abstract
-
- DNA methylation variations in familial female and male breast cancer.
- Abeni E, Grossi I, Marchina E, Coniglio A, Incardona P, Cavalli P, Zorzi F, Chiodera PL, Paties CT, Crosatti M, De Petro G, Salvi A.
- Oncol Lett. 2021 Jun;21(6):468. doi: 10.3892/ol.2021.12729. Epub 2021 Apr 12.
- PMID: 33907578
- PubMed abstract
- Source abstract
-
- Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
- Jiang X, Hu X, Gu Y, Li Y, Jin M, Zhao H, Gao R, Huang Z, Lu J.
- Pathol Res Pract. 2021 May 29;224:153507. doi: 10.1016/j.prp.2021.153507. Epub ahead of print.
- PMID: 34102435
- PubMed abstract
- Source abstract
-
- Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy.
- Hongo H, Kosaka T, Hayashi H, Nakamura K, Nishihara H, Mikami S, Beltran H, Oya M.
- Asian J Androl. 2021 May 21. doi: 10.4103/aja.aja_37_21. Epub ahead of print.
- PMID: 34045389
- PubMed abstract
- Source abstract
- Case report
- Free Full Text
-
- Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
- Dong B, Fan L, Yang B, Chen W, Li Y, Wu K, Zhang F, Dong H, Cheng H, Pan J, Zhu Y, Chi C, Dong L, Sha J, Li L, Yao X, Xue W.
- J Natl Compr Canc Netw. 2021 May 14;19(8):905-914. doi: 10.6004/jnccn.2020.7663.
- PMID: 33990090
- PubMed abstract
-
- Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
- van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
- Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
- PMID: 34067105
- PubMed abstract
- Source abstract
- Review
- Free PMC article
- Free Full Text
-
- The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology.
- Nakken S, Lilleby W, Switlyk MD, Knudsen KE, Lilleby O, Zhao S, Kaveh F, Ekstrøm PO, Urbanucci A, Hovig E.
- J Pers Med. 2021 Apr 22;11(5):330. doi: 10.3390/jpm11050330.
- PMID: 33922147
- PubMed abstract
- Source abstract
- Case report
- Free Full Text
-
- Age-related activity of Poly (ADP-ribose) polymerase (PARP) in men with localized prostate cancer.
- Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M.
- Mech Ageing Dev. 2021 Apr 19:111494. doi: 10.1016/j.mad.2021.111494. Epub ahead of print.
- PMID: 33887280
- PubMed abstract
- Source abstract
-
- Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
- Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E.
- Eur J Cancer. 2021 Feb 22;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub ahead of print.
-
- Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
- Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E.
- Eur J Cancer. 2021 Feb 21;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub ahead of print.
- PMID: 33626496
- PubMed abstract
- Source abstract
-
- Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
- Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons A, Loehr A, Venstrom JM, Oxnard GR.
- Clin Cancer Res. 2021 Feb 8. doi: 10.1158/1078-0432.CCR-20-4805. Epub ahead of print.
- PMID: 33558422
- PubMed abstract
- Source abstract
Commentary, Review:
Liquid Biopsy: It's the Bloody Truth!
- PMID: 33795259
- PubMed abstract
- Source abstract
-
- Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
- Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D.
- Br J Cancer. 2021 Feb;124(3):552-563. doi: 10.1038/s41416-020-01114-x. Epub 2020 Oct 27.
- PMID: 33106584
- PubMed abstract
- Review
- Free PMC article
- Free Full Text
-
- Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
- Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES.
- Mod Pathol. 2021 Jan 18. doi: 10.1038/s41379-020-00731-4. Epub ahead of print.
- PMID: 33462368
- PubMed abstract
- Source abstract
-
- Beware Liquid Biopsies to Guide PARP Blockade.
- [No author given]
- Cancer Discov. 2020 Nov 18. doi: 10.1158/2159-8290.CD-NB2020-105. Epub ahead of print.
- PMID: 33208392
- PubMed abstract
- Source abstract
-
- Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
- Gilson C, Ingleby F, Gilbert DC, Parry MA, Atako NB, Ali A, Hoyle A, Clarke NW, Gannon M, Wanstall C, Brawley C, Mason MD, Malik Z, Simmons A, Loehr A, Parry-Jones A, Eeles R, Kote-Jarai Z, James ND, Amos C, Parmar MKB, Langley RE, Sydes MR, Attard G, Chowdhury S; STAMPEDE Investigators.
- JCO Precis Oncol. 2020 Nov;4:882-897. doi: 10.1200/PO.19.00388.
- PMID: 35050761
- PubMed abstract
- Source abstract
-
- Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case.
- Izawa M, Kosaka T, Nakamura K, Oba J, Hishida T, Hongo H, Mikami S, Nishihara H, Oya M.
- IJU Case Rep. 2020 Oct 15;4(1):14-17. doi: 10.1002/iju5.12224.
- PMID: 33426488
- PubMed abstract
- Source abstract
- Case Report
- Free PMC article
- Free Full Text
-
- Male Breast Cancer in Togo: Imaging and Clinicopathological Findings.
- Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.
- Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067.
- PMID: 32934847
- PubMed abstract
-
- The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis.
- Crumbaker M, Chan EKF, Gong T, Corcoran N, Jaratlerdsiri W, Lyons RJ, Haynes AM, Kulidjian AA, Kalsbeek AMF, Petersen DC, Stricker PD, Jamieson CAM, Croucher PI, Hovens CM, Joshua AM, Hayes VM.
- Cancers (Basel). 2020 May 7;12(5):E1178. doi: 10.3390/cancers12051178.
- PMID: 32392735
- PubMed abstract
- Source abstract
-
- Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
- Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.
- JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30.
- PMID: 32903788
- PubMed abstract
- Source abstract
-
- Germline and somatic DNA repair gene alterations in prostate cancer.
- Dall'Era MA, McPherson JD, Gao AC, DeVere White RW, Gregg JP, Lara PN Jr.
- Cancer. 2020 Apr 21. doi: 10.1002/cncr.32908. [Epub ahead of print]
- PMID: 32315455
- PubMed abstract
- Source abstract
-
- Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer.
- André S, P Nunes S, Silva F, Henrique R, Félix A, Jerónimo C.
- Int J Mol Sci. 2020 Apr 14;21(8). pii: E2715. doi: 10.3390/ijms21082715.
- PMID: 32295201
- PubMed abstract
- Source abstract
-
- Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
- Simmons AD, Nguyen M, Pintus E.
- BMC Cancer. 2020 Mar 14;20(1):215. doi: 10.1186/s12885-020-6657-2.
- PMID: 32171277
- PubMed abstract
- Case report
- Free Full Text
-
- Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
- Sztupinszki Z, Diossy M, Krzystanek M, Börcsök , Pomerantz MM, Tisza V, Spisák S, Rusz O, Csabai I, Freedman ML, Szallasi Z.
- Clin Cancer Res. 2020 Feb 18. pii: clincanres.2135.2019. doi: 10.1158/1078-0432.CCR-19-2135. [Epub ahead of print]
- PMID: 32071115
- PubMed abstract
- Source abstract
-
- BRCA2 and RB1 loss responds to PARP inhibitors.
- Fenner A.
- Nat Rev Urol. 2020 Feb 11. doi: 10.1038/s41585-020-0293-0. [Epub ahead of print]
- PMID: 32047284
- PubMed abstract
- Source abstract
-
- Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.
- Lotan TL, Tomlins SA, Bismar TA, Van der Kwast TH, Grignon D, Egevad L, Kristiansen G, Pritchard CC, Rubin MA, Bubendorf L.
- Am J Surg Pathol. 2020 Feb 10. doi: 10.1097/PAS.0000000000001450. [Epub ahead of print]
- PMID: 32044806
- PubMed abstract
- Source abstract
-
- Genomics of lethal prostate cancer at diagnosis and castration-resistance.
- Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petremolo A, Zafeiriou Z, Fontes MS, Perez-Lopez R, Tunariu N, Fulton BA, Jones R, McGovern UB, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS.
- J Clin Invest. 2019 Dec 24. pii: 132031. doi: 10.1172/JCI132031. [Epub ahead of print]
- PMID: 31874108
- PubMed abstract
- Source abstract
-
- BRCA2 genemutation, c.2808_2811delACAA (p.Ala938Profs), in malebreastcancer - clinicopathologicalanalysisbased on a case report.
- Huszno J, Fiszer-Kierzkowska A, Piglowski W, Mazur M.
- Prz Menopauzalny. 2019 Dec;18(4):227-229. doi: 10.5114/pm.2019.93120. Epub 2020 Jan 15.
- PMID: 32132887
- PubMed abstract
- Source abstract
- Case report
- Free PMC article
- Free Full Text
-
- The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
- van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.
- Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.
- PMID: 31748536
- PubMed abstract
-
- The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
- Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.
- Cancer Immunol Immunother. 2019 Sep 23. doi: 10.1007/s00262-019-02393-x. [Epub ahead of print]
- PMID: 31549213
- PubMed abstract
-
- Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.
- Yadav S, Hart SN, Hu C, Hillman D, Lee KY, Gnanaolivu R, Na J, Polley EC, Couch FJ, Kohli M.
- JCO Precis Oncol. 2019 Sep 17;3:PO.19.00067. doi: 10.1200/PO.19.00067.
- PMID: 32923857
- PubMed abstract
- Source abstract
-
- Vascular endothelium function among male carriers of BRCA 1&2 germline mutation.
- Witberg G, Lev E, Ber Y, Tabachnik T, Sela S, Belo I, Leshem-Lev D, Margel D.
- Oncotarget. 2019 Aug 20;10(49):5041-5051. doi: 10.18632/oncotarget.27118. eCollection 2019 Aug 20.
- PMID: 31489114
- PubMed abstract
- Source abstract
-
- Multi-omics analysis reveals the BRCA1 mutation and mismatch repair gene signatures associated with survival, protein expression, and copy number alterations in prostate cancer.
- Hsiao TH, Chiu YC, Shao YJ.
- Transl Cancer Res. 2019 Aug;8(4):1279-1288. doi: 10.21037/tcr.2019.07.05.
- PMID: 35116870
- PubMed abstract
-
- Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
- Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.
- J Clin Invest. 2019 Jul 16;130. pii: 127613. doi: 10.1172/JCI127613.
- PMID: 31310591
- PubMed abstract
- Source abstract
-
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
- Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno , Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS.
- Eur Urol. 2019 Jul 13. pii: S0302-2838(19)30520-2. doi: 10.1016/j.eururo.2019.06.030. [Epub ahead of print]
- PMID: 31345636
- PubMed abstract
- Source abstract
-
- The molecular genetic make-up of male breast cancer.
- Moelans CB, de Ligt J, van der Groep P, Prins P4, Besselink N, Hoogstraat M, Ter Hoeve N, Lacle M, Kornegoor R, van der Pol C, de Leng W, Barbe E, van der Vegt B, Martens J, Bult P, Smits VT, Koudijs M, Nijman I, Voest E, Selenica P, Weigelt B, Reis-Filho J, van der Wall E, Cuppen E, van Diest PJ.
- Endocr Relat Cancer. 2019 Jul 1. pii: ERC-19-0278. doi: 10.1530/ERC-19-0278. [Epub ahead of print]
- PMID: 31340200
- PubMed abstract
- Source abstract
-
- Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.
- André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE.
- Mol Clin Oncol. 2019 Jun;10(6):644-654. doi: 10.3892/mco.2019.1841. Epub 2019 Apr 8.
- PMID: 31031981
- PubMed abstract
- Source abstract
-
- The influence of BRCA2 mutation on localized prostate cancer.
- Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP.
- Nat Rev Urol. 2019 May;16(5):281-290. doi: 10.1038/s41585-019-0164-8.
- PMID: 30808988
- PubMed abstract
- Review
- Free Full Text
-
- Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
- Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.
- Int J Cancer. 2019 Feb 1;144(3):607-614. doi: 10.1002/ijc.31905. Epub 2018 Oct 22.
- PMID: 30265376
- PubMed abstract
- Source abstract
-
- Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.
- Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.
- Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.
- PMID: 29725535
- PubMed abstract
- Source abstract
- Case report
- Free PMC article
- Free Full Text (PDF)
-
- Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers.
- Rizzolo P, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Palli D, Ottini L.
- Oncotarget. 2018 Apr 13;9(28):19783-19792. doi: 10.18632/oncotarget.24856. eCollection 2018 Apr 13.
- PMID: 29731982
- PubMed abstract
- Source abstract
-
- DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
- Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.
- Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6.
- PMID: 29287968
- PubMed abstract
- Source abstract
-
- Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
- Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.
- Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25.
- PMID: 29368341
- PubMed abstract
- Source abstract
-
- Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?
- Ben-Aharon I, Levi M, Margel D, Yerushalmi R, Rizel S, Perry S, Sharon E, Hasky N, Abir R, Fisch B, Tobar A, Shalgi R, Stemmer SM.
- Oncotarget. 2018 Mar 23;9(22):15931-15941. doi: 10.18632/oncotarget.24638. eCollection 2018 Mar 23.
- PMID: 29662617
- PubMed abstract
- Source abstract
-
- Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
- Ibrahim M, Yadav S, Ogunleye F, Zakalik D.
- BMC Cancer. 2018 Feb 13;18(1):179. doi: 10.1186/s12885-018-4098-y.
- PMID: 29433453
- PubMed abstract
-
- BRCA2 carriers with male breast cancer show elevated tumour methylation.
- Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA, Investigators K, Dobrovic A, Fox SB.
- BMC Cancer. 2017 Sep 11;17(1):641. doi: 10.1186/s12885-017-3632-7.
- PMID: 28893223
- PubMed abstract
-
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
- Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW.
- Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.
- PMID: 28259476
- PubMed abstract
- Source abstract
-
- Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
- Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.
- JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.
- PMID: 28825054
- PubMed abstract
- Source abstract
-
- Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
- Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.
- Nat Commun. 2017 Jan 9;8:13671. doi: 10.1038/ncomms13671.
- PMID: 28067867
- PubMed abstract
Research News:
Prostate cancer: Genomic drivers of BRCA2-mutant tumours.
- PMID: 28117848
- PubMed abstract
- Source abstract
-
- Male Breast Cancer.
- Serdy KM, Leone JP, Dabbs DJ, Bhargava R.
- Am J Clin Pathol. 2017 Jan 1;147(1):110-119. doi: 10.1093/ajcp/aqw207.
- PMID: 28171879
- PubMed abstract
- Source abstract
-
- Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.
- Rizzolo P, Navazio AS, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Scarnò M, Tommasi S, Palli D, Ottini L.
- Oncotarget. 2016 Nov 8;7(45):74097-74106. doi: 10.18632/oncotarget.12272.
- PMID: 27765917
- PubMed abstract
- Source abstract
-
- EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
- Navazio AS, Rizzolo P, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Tommasi S, Palli D, Ottini L.
- Breast Cancer Res Treat. 2016 Nov;160(1):181-186. doi: 10.1007/s10549-016-3976-8. Epub 2016 Sep 15.
- PMID: 27628328
- PubMed abstract
- Source abstract
-
- The Significance of Proteomic Biomarkers in Male Breast Cancer.
- Zografos E, Gazouli M, Tsangaris G, Marinos E.
- Cancer Genomics Proteomics. 2016 05-06 [2016 May-Jun;]13(3):183-190.
- PMID: 27107060
- PubMed abstract
- Source abstract
- Review
- Free Full Text
-
- Male breast cancer is not congruent with the female disease.
- Fentiman IS.
- Crit Rev Oncol Hematol. 2016 May;101:119-24. doi: 10.1016/j.critrevonc.2016.02.017. Epub 2016 Feb 27.
- PMID: 26989051
- PubMed abstract
- Source abstract
- Review
- Free Full Text
-
- Genomic profiling of male breast cancer.
- Burki TK.
- Lancet Oncol. 2016 Apr;17(4):e141. doi: 10.1016/S1470-2045(16)00179-0. Epub 2016 Mar 18.
- PMID: 26997141
- PubMed abstract
- Source abstract
-
- Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer.
- Zorrieh Zahra A, Kadkhoda S, Behjati F, Aghakhani Moghaddam F, Badiei A, Sirati F, Afshin Alavi H, Atri M, Omranipour R, Keyhani E.
- Int J Mol Cell Med. 2016 Spring;5(2):114-22. Epub 2016 May 9.
- PMID: 27478808
- PubMed abstract
- Source abstract
-
- Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
- Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S; EMBRACE, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L.
- Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.
- PMID: 26857456
- PubMed abstract
Blog post: New insights into the role of gender in breast cancer development. (On Medicine)
-
- The cancer genetics and pathology of male breast cancer.
- Deb S, Lakhani SR, Ottini L, Fox SB.
- Histopathology. 2016 Jan;68(1):110-8. doi: 10.1111/his.12862.
- PMID: 26768033
- PubMed abstract
- Source abstract
- Review
- Free Full Text
-
- BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
- de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P.
- Fam Cancer. 2015 Dec;14(4):505-13. doi: 10.1007/s10689-015-9814-z.
- PMID: 26026974
- PubMed abstract
- Source abstract
-
- Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
- Biesma HD, Schouten PC, Lacle MM, Sanders J, Brugman W, Kerkhoven R, Mandjes I, van der Groep P, van Diest PJ, Linn SC.
- Genes Chromosomes Cancer. 2015 Dec;54(12):734-44. doi: 10.1002/gcc.22284. Epub 2015 Sep 10.
- PMID: 26355282
- PubMed abstract
- Source abstract
-
- MicroRNA expression profiling in male and female familial breast cancer.
- Pinto R, De Summa S, Danza K, Popescu O, Paradiso A, Micale L, Merla G, Palumbo O, Carella M, Tommasi S.
- Br J Cancer. 2014 Dec 9;111(12):2361-2368. doi: 10.1038/bjc.2014.535. Epub 2014 Nov 13.
- PMID: 25393370
- PubMed abstract
- Source abstract
-
- Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.
- Danza K, De Summa S, Pilato B, Carella M, Palumbo O, Popescu O, Paradiso A, Pinto R, Tommasi S.
- J Transl Med. 2014 Nov 19;12(1):319. doi: 10.1186/s12967-014-0319-6.
- PMID: 25406994
- PubMed abstract
-
- Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.
- Deb S, Johansson I, Byrne D, Nilsson C, Investigators k, Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I, Fox SB.
- Mod Pathol. 2014 Sep;27(9):1223-30. doi: 10.1038/modpathol.2013.231. Epub 2014 Jan 24.
- PMID: 24457463
- PubMed abstract
- Source abstract
-
- Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status.
- Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators, Kote-Jarai Z, Eeles RA.
- PLoS One. 2014 Jan 29;9(1):e86659. doi: 10.1371/journal.pone.0086659. eCollection 2014.
- PMID: 24489760
- PubMed abstract
-
- Male breast cancer: genetics, epigenetics, and ethical aspects.
- Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L.
- Ann Oncol. 2013 Nov;24 Suppl 8:viii75-viii82. doi: 10.1093/annonc/mdt316.
- PMID: 24131976
- PubMed abstract
- Source abstract
- Review
- Free Full Text
-
- BRCA1 and p53 regulate critical prostate cancer pathways.
- De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, De Siervi A.
- Prostate Cancer Prostatic Dis. 2013 Sep;16(3):233-8. doi: 10.1038/pcan.2013.12. Epub 2013 May 14.
- PMID: 23670255
- PubMed abstract
- Source abstract
-
- Different methylation and microRNA expression pattern in male and female familial breast cancer.
- Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S.
- J Cell Physiol. 2013 Jun;228(6):1264-9. doi: 10.1002/jcp.24281.
- PMID: 23160909
- PubMed abstract
- Source abstract
-
- Male breast cancer according to tumor subtype and race : A population-based study.
- Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH.
- Cancer. 2013 May 1;119(9):1611-7. doi: 10.1002/cncr.27905. Epub 2013 Jan 22.
- PMID: 23341341
- PubMed abstract
- Source abstract
-
- SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?
- Palli D, Rizzolo P, Zanna I, Silvestri V, Saieva C, Falchetti M, Navazio AS, Graziano V, Masala G, Bianchi S, Russo A, Tommasi S, Ottini L.
- J Cell Mol Med. 2013 May;17(5):605-7. doi: 10.1111/jcmm.12043.
- PMID: 23711090
- PubMed abstract
- Source abstract
-
- Male breast cancer, age and sex chromosome aneuploidy.
- Jacobs PA, Maloney V, Cooke R, Crolla JA, Ashworth A, Swerdlow AJ.
- Br J Cancer. 2013 Mar 5;108(4):959-63. doi: 10.1038/bjc.2012.577. Epub 2013 Jan 8.
- PMID: 23299533
- PubMed abstract
- Source abstract
-
- PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
- Deb S, Do H, Byrne D, Jene N; kConFab Investigators, Dobrovic A, Fox SB.
- Breast Cancer Res. 2013;15(4):R69.
- PMID: 23971979
- PubMed abstract
-
- High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
- Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators, Fox S, Thorne H.
- BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.
- PMID: 23035815
- PubMed abstract
- Source abstract
-
- Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
- Deb S, Jene N; Kconfab Investigators, Fox SB.
- BMC Cancer. 2012 Nov 9;12:510. doi: 10.1186/1471-2407-12-510.
- PMID: 23146383
- PubMed abstract
-
- Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
- Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MCh, de Bruin PC, Oudejans JJ, van Diest PJ.
- Breast Cancer Res. 2012 Jul 5;14(4):R101. doi: 10.1186/bcr3220.
- PMID: 22765268
- PubMed abstract
-
- Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy.
- Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D.
- Breast Cancer Res Treat. 2012 Jul;134(1):411-8. doi: 10.1007/s10549-012-2062-0. Epub 2012 Apr 18.
- PMID: 22527108
- PubMed abstract
- Source abstract
Comments from NSGC Discussion Forum Cancer SIG